Abstract 1544P
Background
Although STSs are rare, the incidences among different geographic and ethnical populations have not been investigated thoroughly. Differences in cancer incidences may signal different underlying biology.
Methods
STS pts from 2013 to 2016 were obtained from National Cancer Registry Databases from France and Taiwan. We selected five most common lineage-specific STS histologies (liposarcoma (LPS), leiomyosarcoma (LMS), angiosarcoma (AS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumor(MPNST)) to estimate the age-standardized incidence rates (ASR, as in per one-million person years). Taiwan ASR was standardized using the French population. The histology and body parts criteria were based on International Classification of Disease for Oncology 3rd edition (ICD-O-3).
Results
A total of 9398 (France 7148, Taiwan 2250) pts are included in the analysis. The ASR of all 5 histologies are significantly different (non-overlapping of the 95% CI) (Table). The ASRs of AS (5.4 vs 2.8) and MPNST (2.0 vs 1.0) are significantly higher in Taiwan; France has significantly higher LPS (12.0 vs 10.0), LMS (9.7 vs 7.6), and SS (1.7 vs 1.2) ASRs. Age distribution patterns demonstrate that LMS (p < 0.001) and LPS (p < 0.001) patients in Taiwan have a younger age peak than those in France. The body part distributions are also significantly different. French patients are more likely to have extremity and truncal MPNST (OR 1.55, p = 0.01), LPS (OR 1.37, p < 0.001) and breast AS (OR 10.6, p < 0.001). Taiwanese pts have higher odds for liver AS (OR 10.7, p < 0.001) and uterine LMS (OR 3.21, p < 0.001). SS age distribution and body parts are not significantly different between the two countries. Table: 1544P
The ASR and 95% CI between France and Taiwan, 2013-2016
| ASR per million person years (95% CI) | ||
| France | Taiwan | |
| Angiosarcoma | 2.8 (2.56-2.96) | 5.4 (4.95-5.93) |
| Leiomyosarcoma | 9.7 (9.29-10.05) | 7.6 (6.98-8.13) |
| Liposarcoma | 12.0 (11.54-12.37) | 10.0 (9.37-10.70) |
| MPNST | 1.0 (0.88-1.13) | 2.0 (1.70-2.29) |
| Synovial sarcoma | 1.7 (1.52-1.84) | 1.2 (0.94-1.40) |
Conclusions
The significant differences in incidence and clinical characteristics of STS suggest that geographic (environmental) and ethnicity factors play an important role in the pathogenesis of STS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Taiwan University Health Data Research Center.
Disclosure
T.W. Chen: Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: Eli Lilly; Financial Interests, Personal, Invited Speaker: TTY; Financial Interests, Personal, Advisory Board: Eisai; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Personal, Advisory Board: TTY; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Advisory Board: Blueprint; Financial Interests, Institutional, Research Grant, IIT study: Eisai; Financial Interests, Institutional, Research Grant, Preclinical: AstraZeneca. K..A. Chan: Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Research Grant: Boehringer Ingelheim; Financial Interests, Personal, Research Grant: MSD; Financial Interests, Personal, Research Grant: MundiPharma; Financial Interests, Personal, Research Grant: Takeda; Financial Interests, Personal, Research Grant: Amgen; Financial Interests, Personal, Research Grant: Bayer. All other authors have declared no conflicts of interest.